PofoliaShared via Pofolia

Journal of Functional Foods· 2026Q1

Heat-killed postbiotic EF-2001® improves gastrointestinal health in overweight adults: A randomized, double-blind, placebo-controlled trial

Ranjith Kumar Manoharan, Hyun-Dong Shin, Yura Lee, Sunhwa Baek et al.

Short summary

Supplementation with heat-killed Enterococcus faecalis EF-2001® (≥30 billion cells/day) for 84 days significantly reduced gastrointestinal symptoms (GSRS score decrease of 9.92 units, p=0.0167) in overweight adults compared to placebo.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Heat-killed EF-2001® (≥30 billion cells/day) significantly reduced total GI symptoms (GSRS) by 9.92 units vs. placebo over 84 days (p=0.0167).
  • Participants taking EF-2001® also reported significantly lower perceived stress (p=0.0163) and improved digestion-associated quality of life (p=0.0114).
  • Exploratory metagenomic analysis indicated directional increases in Lactobacillus, Megamonas, and Bifidobacterium, and decreases in Escherichia and Klebsiella.
  • No significant changes were observed in serum TNF-α or lipid parameters.

AI-generated from the title and abstract; the full text is not read.

Abstract

A diverse, functionally resilient gut microbiome supports metabolic, immune, and gastrointestinal (GI) health. This trial evaluated heat-killed Enterococcus faecalis EF-2001 (EF-2001®) on GI symptoms, quality of life, and gut microbiome composition in adults with excess weight and mild-to-moderate GI discomfort. In this 84-day randomized, double-blind, placebo-controlled, parallel-group trial, 209 adults aged 18–45 years were randomized (1:1:1) to receive EF-2001® (≥30 billion cells/day), beLP1® (reported separately), or placebo once daily after breakfast. Per-protocol analyses included 49 participants in the EF-2001® group and 54 in the placebo group. The primary endpoint was change in gastrointestinal symptoms assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Secondary endpoints included perceived stress (PSS), digestion-associated quality of life (DQLQ), serum TNF-α, lipid parameters, body composition (DEXA), and gut microbiome composition assessed by metagenomic next-generation sequencing. By Day 84, EF-2001® significantly reduced total GSRS scores compared with placebo (mean decrease 9.92 [SD 7.16] units; p = 0.0167). Significant improvements were also observed in perceived stress (PSS decrease 3.45 [SD 6.40] units; p = 0.0163) and digestion-associated quality of life (DQLQ decrease 1.25 [SD 1.90] units; p = 0.0114). Shotgun metagenomic analysis identified exploratory shifts in the gut microbiome, with directional increases in Lactobacillus , Megamonas , and Bifidobacterium and reductions in Escherichia and Klebsiella . However, no taxa reached significance after FDR correction. Serum TNF-α showed a small reduction, while lipid parameters changed minimally. EF-2001® supplementation for 84 days improved GI symptoms, perceived stress and digestion-associated quality of life, while exploratory microbiome analyses identified directional changes in selected taxa.

The authors' abstract, as published at the source. Journal of Functional Foods, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Food Science

Food ScienceAgricultural and Biological Sciences